9770
0
Posted on Oct 04, 2002, 7 a.m.
By Bill Freeman
Neurologist Dr. Steven Schwid of the University of Rochester in New York conducted a study to evaluate the use of remacemide (AstraZeneca Plc), when added to drugs such as levodopa, in reducing symptoms and slowing the progression of Parkinson's Disease. Research has suggested that over-activity of a neurotransmitter in the brain called glutamate, a protein precursor that causes excitation of certain brain cells or neurons, which may lead to brain cell death and Parkinson's progression.
Neurologist Dr. Steven Schwid of the University of Rochester in New York conducted a study to evaluate the use of remacemide (AstraZeneca Plc), when added to drugs such as levodopa, in reducing symptoms and slowing the progression of Parkinson's Disease. Research has suggested that over-activity of a neurotransmitter in the brain called glutamate, a protein precursor that causes excitation of certain brain cells or neurons, which may lead to brain cell death and Parkinson's progression. Remacemide interferes with glutamate.
SOURCE/REFERENCE: Neurology, April 24, 2000
